News

Julie C. Martin DNP, AOCN, FNP-BC, discusses best practices to approaching conversations on clinically actionable genomic results with patients.

An analysis of the cilta-cel safety profile yielded promising results, according to nurse investigators.

Victoria R. Crowder, BSN, RN, and co-investigators, highlight existing gaps in the understanding of malnutrition risks facing patients with acute myeloid leukemia and myelodysplastic syndromes.

Monitoring patients for cytokine release syndrome is a key aspect of caring for patients receiving teclistamab.

Ashley Marenyi, RN, BSN, OCN, highlights the importance of counseling patients with head and neck cancer on the short-term and long-term adverse effects of radiation treatment.

Specialists highlight the best practices and latest treatment regimens for patients presenting with myelofibrosis, polycythemia vera, and essential thrombocythemia.

Denise Nicholson, BSN, RN, explains the importance of advance care planning, and how oncology nurses can effectively facilitate these conversations.

Patients with PD-L1–positive, human papillomavirus 16–positive advanced, cervical cancer derived a median overall survival greater than 25 months with VB10.16/atezolizumab.

The FDA has pushed back the PDUFA date for quizartinib for select patients with acute myeloid leukemia.

Data that was leaked from a 2023 EHA Hybrid Congress Abstracts demonstrated that ciltacabtagene autoleucel reduced the risk of disease progression in patients with relapsed/refractory multiple myeloma.

An estimated 54.5% of adolescents in the United States have received the recommended doses of the HPV vaccine, although the government established a goal of an 80% vaccination rate in this population.

Trifluridine plus tipiracil, with or without bevacizumab, has been granted priority review status for the treatment of refractory, metastatic colorectal cancer.

Milademetan, a MDM2 inhibitor, is associated with thrombocytopenia. An intermittent dosing schedule may help mitigate that adverse event.

Combined adjuvant treatment with mRNA-4157 in combination with pembrolizumab improved recurrence rates in patients with resected high-risk melanoma.

Beth Faiman, PhD, MSN, APRN-BC, AOCN, discusses the growing need for advanced practitioner provider education and her role with the NP/PA center of excellence.

Patients who received pembrolizumab plus cisplatin and gemcitabine achieved a median overall survival of 12.7 months, compared with 10.9 months with cisplatin and gemcitabine alone.

A genome-wide methylome enrichment platform may help identify multiple early-stage cancers.

Sarah Yenser Wood, RN, MSN, ANP, AOCNP, leads a nursing panel on adverse event management in renal cell carcinoma.

Polatuzumab vedotin has been approved in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone for previously untreated diffuse large B-cell lymphoma.

The pathologic complete response rate with durvalumab was 17.2% vs 4.3% with placebo, reflecting an absolute difference of 12.9%.

Applying the local anesthetic lidocaine preceding surgery yielded significant survival benefits for patients with early-stage breast cancer.

Findings from the TAPESTRY trial showed that approximately 40% of patients with genetic conditions may be missed by current NCCN guidelines.

92% of those over 70 say they are comfortable with telehealth.

Omidubicel has been approved to quicken the recovery of neutrophils and reduce the risk of infection following stem cell transplant.

Combined adjuvant treatment with atezolizumab and bevacizumab was determined to deliver a statistically significant recurrence-free survival benefit to patients with resected hepatocellular carcinoma.

Investigators continue to explore new ways to manage colorectal cancer with a BRAF V600E mutation.

Patients with TKI-naïve and crizotinib-pretreated ROS-positive non–small cell lung cancer continued to show responses to treatment with taletrectinib.

The overall response rate with durvalumab and guadecitabine was 23% in patients with advanced ccRCC who had received 1 or fewer therapies.

AbbVie has withdrawn the indications for previously pretreated patients with mantle cell lymphoma and marginal zone lymphoma.